Genentech: Press Releases | Friday, Sep 13, 2024
Sep 13, 2024 · Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Genentech: News Features | FDA Approves the First and Only …
On September 13, 2024, the FDA approved Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in adults.
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
Sep 16, 2024 · The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab), for...
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO …
Sep 13, 2024 · "We are pleased that the subcutaneous formulation of OCREVUS, OCREVUS ZUNOVO, which contains our ENHANZE drug delivery technology, is now approved in the U.S. for patients with these two...
FDA approves OCREVUS ZUNOVO™ as the first and only
Sep 16, 2024 · OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's office. This approval is backed by a decade of ...
FDA approves injectable Ocrevus Zunovo for relapsing, …
Sep 26, 2024 · The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with...
FDA Approves Ocrevus Zunovo for 2 Forms of Multiple Sclerosis
Sep 13, 2024 · The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The approval marks the first and only twice yearly, health care professional-administrated subcutaneous (SC) injections for both forms of MS. 1
FDA approves Roche’s Ocrevus Zunovo - Pharmaceutical …
Sep 16, 2024 · Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics‘s Enhanze drug delivery technology.
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO …
Sep 13, 2024 · "We are pleased that the subcutaneous formulation of OCREVUS, OCREVUS ZUNOVO, which contains our ENHANZE drug delivery technology, is now approved in the U.S. for patients with these two forms...
Subcutaneous Ocrevus Zunovo Approved as Treatment for …
Sep 17, 2024 · The Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq; Genentech, South San Francisco, CA) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).